Cytek Biosciences Valuation

Is 8EQ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 8EQ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 8EQ (€6.2) is trading below our estimate of fair value (€50.48)

Significantly Below Fair Value: 8EQ is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 8EQ?

Key metric: As 8EQ is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 8EQ. This is calculated by dividing 8EQ's market cap by their current revenue.
What is 8EQ's PS Ratio?
PS Ratio4.3x
SalesUS$201.21m
Market CapUS$843.71m

Price to Sales Ratio vs Peers

How does 8EQ's PS Ratio compare to its peers?

The above table shows the PS ratio for 8EQ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.1x
EVT Evotec
2.1x12.1%€1.7b
GXI Gerresheimer
1.3x10.3%€2.6b
1SXP SCHOTT Pharma KGaA
4.3x10.7%€4.0b
SRT3 Sartorius
4.5x9.3%€13.6b
8EQ Cytek Biosciences
4.3x11.7%€843.7m

Price-To-Sales vs Peers: 8EQ is expensive based on its Price-To-Sales Ratio (4.3x) compared to the peer average (3.1x).


Price to Sales Ratio vs Industry

How does 8EQ's PS Ratio compare vs other companies in the European Life Sciences Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
8EQ 4.3xIndustry Avg. 4.4xNo. of Companies9PS03.26.49.612.816+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 8EQ is good value based on its Price-To-Sales Ratio (4.3x) compared to the European Life Sciences industry average (4.3x).


Price to Sales Ratio vs Fair Ratio

What is 8EQ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

8EQ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.3x
Fair PS Ratio2.6x

Price-To-Sales vs Fair Ratio: 8EQ is expensive based on its Price-To-Sales Ratio (4.3x) compared to the estimated Fair Price-To-Sales Ratio (2.6x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 8EQ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€6.20
€7.88
+27.2%
8.7%€8.45€6.57n/a5
Nov ’25€4.52
€7.45
+64.8%
9.9%€8.27€6.44n/a5
Oct ’25€4.88
€7.88
+61.5%
20.4%€10.87€6.34n/a5
Sep ’25€5.05
€7.93
+57.0%
20.4%€10.93€6.38n/a5
Aug ’25€6.15
€8.81
+43.2%
14.9%€11.12€7.42n/a5
Jul ’25€5.10
€8.81
+72.7%
14.9%€11.12€7.42n/a5
Jun ’25€5.15
€8.81
+71.0%
14.9%€11.12€7.42n/a5
May ’25€5.50
€9.21
+67.5%
11.0%€11.05€8.29n/a5
Apr ’25n/a
€9.36
0%
9.6%€11.01€8.26n/a5
Mar ’25n/a
€9.71
0%
10.6%€11.10€8.33n/a4
Feb ’25n/a
€9.22
0%
17.9%€11.06€6.45n/a5
Jan ’25n/a
€8.81
0%
18.2%€11.01€6.42n/a5
Dec ’24n/a
€8.91
0%
19.0%€11.25€6.56n/a4
Nov ’24€3.92
€10.39
+164.9%
32.1%€16.05€7.55€4.524
Oct ’24€5.65
€12.76
+125.8%
16.0%€15.49€10.02€4.884
Sep ’24€6.90
€12.76
+84.9%
16.0%€15.49€10.02€5.054
Aug ’24€8.05
€12.47
+54.9%
16.0%€15.14€9.80€6.154
Jul ’24€7.45
€12.98
+74.2%
13.5%€15.48€10.93€5.104
Jun ’24€7.20
€12.98
+80.2%
13.5%€15.48€10.93€5.154
May ’24€9.75
€14.07
+44.3%
8.2%€15.94€13.13€5.504
Apr ’24€8.05
€14.07
+74.7%
8.2%€15.94€13.13n/a4
Mar ’24€9.55
€14.77
+54.7%
11.3%€16.88€13.13n/a4
Feb ’24€10.90
€15.52
+42.4%
6.8%€16.93€14.11n/a4
Jan ’24€9.50
€15.52
+63.4%
6.8%€16.93€14.11n/a4
Dec ’23€13.60
€15.80
+16.2%
7.6%€17.42€14.51n/a3
Nov ’23€15.30
€15.86
+3.6%
5.1%€16.85€14.87€3.923

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies